On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

HIMS stock up 16% on Wednesday, continuing month-long gains. Novo Nordisk ends partnership, cites misleading marketing and ...

HIMS accelerates its global push with the ZAVA acquisition and a planned Canada launch targeting affordable obesity care.

The more cautious voices point to Hims’s high P/E ratio and recent volatility, warning that the stock could cool off after its sharp run-up. That said, a few analysts are still pretty optimistic. They ...

Hims & Hers Health recurring revenue grew 111% YoY, boosted by personalization and chronic care. Forecasting $2.35B revenue ...

On today's episode of The Roommates Show the guys hand out their NBA Awards! They relive their most controversial moments, ...

Justin Penik invites the Giants RB1 Tyrone Tracy Jr. to the Jomboy Media Office to talk about his rookie season, goals going ...

Shark attack survivor Paul de Gelder joins us to talk Navy diving, bull sharks, and his wild return in Air Jaws and more ...

Analysts have provided Laboratory Corp with 8 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $276.5, suggesting a potential 9.69% upside.

Dr. Garshick suggests pairing tretinoin with hyaluronic acid and ceramides to combat any dryness or irritation that you might ...

Morningstar analyst Nicolas Owens breaks down airline earnings, as Delta restores its guidance and signals a clearer outlook ...